TY - JOUR
T1 - Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic
AU - Rice, Kevin
AU - Hudak, Jane
AU - Peay, Kimberly
AU - Elsamanoudi, Sally
AU - Travis, Judith
AU - Lockhart, Robbin
AU - Cullen, Jennifer
AU - Black, Libby
AU - Houge, Susan
AU - Brassell, Stephen
PY - 2010/11
Y1 - 2010/11
N2 - Objectives: To identify racial and demographic factors that influence treatment choice and its resulting impact on health-related quality of life (HRQoL) for prostate cancer patients. Methods: Patients presenting to an equal access, military, multidisciplinary prostate cancer clinic composed the study group. The Expanded Prostate Cancer Index Composite (EPIC), EPIC Demographic, and Medical Outcomes Study Short Form 36 were the instruments used. Evaluation was performed before treatment and every 3 months after treatment. Results: The study group comprised 665 patients. Caucasians were 3-fold more likely to choose surgery (radical prostatectomy [RP]) over external beam radiation therapy (EBRT). Patients who earned more than $100 000 annually disproportionately chose RP (P <.0001). Similarly, those having a graduate school degree disproportionally chose RP (P <.0001). Patients undergoing RP had the greatest risk of urinary function decline (P <.0001) and sexual bother (P = .0003). African Americans (AA) had a greater risk of urinary function decline irrespective of treatment choice. Patients undergoing EBRT had equivalent urinary function to expectant management (EM) at 12 months (P <.0001). Brachytherapy was the only treatment that posed an increased risk of urinary bother decline when compared with EM (P = .0217). EBRT alone did not show significant decrement in sexual function when compared with EM. Conclusions: RP was chosen by patients of Caucasian ethnicity and patients with higher income and education level, despite providing the greatest risk of HRQoL decline. EBRT had no significant impact on urinary function, sexual function, or sexual bother scores at 12 months. EBRT may be offered to older patients with minimal HRQoL impact. Pretreatment counseling of HRQoL outcomes is essential to overall prostate cancer management.
AB - Objectives: To identify racial and demographic factors that influence treatment choice and its resulting impact on health-related quality of life (HRQoL) for prostate cancer patients. Methods: Patients presenting to an equal access, military, multidisciplinary prostate cancer clinic composed the study group. The Expanded Prostate Cancer Index Composite (EPIC), EPIC Demographic, and Medical Outcomes Study Short Form 36 were the instruments used. Evaluation was performed before treatment and every 3 months after treatment. Results: The study group comprised 665 patients. Caucasians were 3-fold more likely to choose surgery (radical prostatectomy [RP]) over external beam radiation therapy (EBRT). Patients who earned more than $100 000 annually disproportionately chose RP (P <.0001). Similarly, those having a graduate school degree disproportionally chose RP (P <.0001). Patients undergoing RP had the greatest risk of urinary function decline (P <.0001) and sexual bother (P = .0003). African Americans (AA) had a greater risk of urinary function decline irrespective of treatment choice. Patients undergoing EBRT had equivalent urinary function to expectant management (EM) at 12 months (P <.0001). Brachytherapy was the only treatment that posed an increased risk of urinary bother decline when compared with EM (P = .0217). EBRT alone did not show significant decrement in sexual function when compared with EM. Conclusions: RP was chosen by patients of Caucasian ethnicity and patients with higher income and education level, despite providing the greatest risk of HRQoL decline. EBRT had no significant impact on urinary function, sexual function, or sexual bother scores at 12 months. EBRT may be offered to older patients with minimal HRQoL impact. Pretreatment counseling of HRQoL outcomes is essential to overall prostate cancer management.
UR - http://www.scopus.com/inward/record.url?scp=78149362565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78149362565&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2010.03.087
DO - 10.1016/j.urology.2010.03.087
M3 - Article
C2 - 20579698
AN - SCOPUS:78149362565
SN - 0090-4295
VL - 76
SP - 1231
EP - 1238
JO - Urology
JF - Urology
IS - 5
ER -